**Note this is an early release from the Annual Meeting of the European Association for the Study of Diabetes [EASD]. Please credit the meeting when using this research*

A nationwide study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found that people with type 2 diabetes (T2D) have a higher risk of developing cancer, with cancer incidence rising more among people with T2D than those without diabetes over the past 25 years, largely driven by obesity-related cancers.

Jefferson researchers work on prompting women who are at risk for lung cancer to get mammograms.

Penn Medicine experts are participating in the ASTRO Annual Meeting, where Neha Vapiwala, MD, will wrap up her term as president of the organization.

Until now, diagnosing skin tumors has relied on detecting visible changes to the skin. Line-Field Confocal Optical Coherence Tomography (LC-OCT) is a well-established method used for diagnosis. Now, researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) led by Dr. Moritz Ronicke from the Department of Dermatology at Uniklinikum Erlangen have developed a new approach: In a feasibility study, the team introduced a procedure involving systematic screening of the faces of patients at a high risk of developing skin cancer. Using this procedure, researchers succeeded for the first time in detecting basal cell carcinoma even before any visible changes to the skin developed.

Migraines, neck pain and other conditions linked to breast size, according to new research from Wake Forest University School of Medicine researchers.

A new study published in Molecular Therapy, led by Prof. LI Yang and with Dr. YUAN Feng as the first author, from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences (CAS), reports a strategy that uses the host lung as an in vivo bioreactor, generating functional memory-like NK cells directly in the body without ex vivo cell manipulation.

The University of Birmingham and Imperial College London have announced the launch of Intelligent Mass Spec Solutions Ltd (IMS Solutions), a new spin-out that is set to revolutionise diagnosis of conditions featuring disordered steroid hormone metabolism.